Pancreatic cancer cell (PDAC)

Pancreatic cancer cells, predominantly Pancreatic Ductal Adenocarcinoma (PDAC) cells, are the malignant drivers of a highly aggressive and lethal disease of the exocrine pancreas [1]. These cells are characterized by near-universal mutations in the KRAS oncogene (found in over 90% of cases), alongside significant alterations in TP53, SMAD4, and CDKN2A, which together drive uncontrolled proliferation and resistance to programmed cell death [2]. Biologically, they exhibit a unique ability to survive within a dense, hypoxic, and nutrient-poor desmoplastic stroma, which also serves as a physical barrier to therapeutic drug delivery [3]. While not a singular molecular target themselves, these cells are the subject of multi-modal treatment strategies including cytotoxic chemotherapies like gemcitabine and nab-paclitaxel, and increasingly, targeted therapies directed at specific genetic vulnerabilities such as KRAS G12C or BRCA mutations [4]. The interaction between these cells and their immunosuppressive tumor microenvironment remains a primary challenge in achieving durable clinical responses [5].

Other names

Pancreatic adenocarcinoma cellMalignant pancreatic cellPDAC cellPancreatic tumor cellPancreatic ductal adenocarcinoma cell

Drugs targeting pancreatic cancer cells utilize diverse mechanisms: antimetabolites (Gemcitabine, 5-FU) inhibit DNA synthesis; taxanes (Paclitaxel) stabilize microtubules to stop mitosis; targeted inhibitors block mutant KRAS signaling (Sotorasib) or EGFR kinase activity (Erlotinib); and PARP inhibitors (Olaparib) induce synthetic lethality in cells with DNA repair deficiencies.